The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer
Publication type: Journal Article
Publication date: 2018-02-03
scimago Q1
wos Q1
SJR: 4.727
CiteScore: 25.5
Impact factor: 17.5
ISSN: 24058033, 24058025
PubMed ID:
29458961
Cancer Research
Oncology
Abstract
Drug resistance is a serious impediment to the treatment of cancer. However, the mechanisms involved remain poorly understood. While it is widely held that the phenomenon is genetic in nature, emerging evidence suggests that non-genetic mechanisms may also be important. Furthermore, at least in some cases, refractoriness to treatment can be reversed by epigenetic reprogramming, and combination and intermittent therapies, as opposed to sustained monotherapy, appear more effective in attenuating it. Here we iterate the confusion in understanding the phenomenon by which cancer cells evade drug response and underscore the need to recognize the genetic/non-genetic duality of drug resistance in cancer. We discuss how ecological and evolutionary principles may help to reconcile the duality and may even offer new treatment strategies.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
Cancers
8 publications, 3.4%
|
|
|
Trends in Cancer
7 publications, 2.98%
|
|
|
iScience
6 publications, 2.55%
|
|
|
Frontiers in Oncology
5 publications, 2.13%
|
|
|
International Journal of Molecular Sciences
4 publications, 1.7%
|
|
|
Journal of Clinical Medicine
4 publications, 1.7%
|
|
|
Scientific Reports
4 publications, 1.7%
|
|
|
BMC Cancer
4 publications, 1.7%
|
|
|
Biomolecules
3 publications, 1.28%
|
|
|
Signal Transduction and Targeted Therapy
3 publications, 1.28%
|
|
|
Nature Communications
3 publications, 1.28%
|
|
|
Nature Reviews Cancer
3 publications, 1.28%
|
|
|
Nature Genetics
3 publications, 1.28%
|
|
|
npj Systems Biology and Applications
3 publications, 1.28%
|
|
|
eLife
3 publications, 1.28%
|
|
|
Journal of Theoretical Biology
3 publications, 1.28%
|
|
|
Annual Review of Cancer Biology
3 publications, 1.28%
|
|
|
Oncotarget
2 publications, 0.85%
|
|
|
Epigenetics Insights
2 publications, 0.85%
|
|
|
Cells
2 publications, 0.85%
|
|
|
Nature
2 publications, 0.85%
|
|
|
Cancer Cell International
2 publications, 0.85%
|
|
|
Journal of Biosciences
2 publications, 0.85%
|
|
|
Oncogene
2 publications, 0.85%
|
|
|
British Journal of Cancer
2 publications, 0.85%
|
|
|
Drug Resistance Updates
2 publications, 0.85%
|
|
|
Biomedicine and Pharmacotherapy
2 publications, 0.85%
|
|
|
International Journal of Biological Macromolecules
2 publications, 0.85%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
2 publications, 0.85%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
10
20
30
40
50
60
|
|
|
Springer Nature
54 publications, 22.98%
|
|
|
Elsevier
46 publications, 19.57%
|
|
|
MDPI
25 publications, 10.64%
|
|
|
Cold Spring Harbor Laboratory
25 publications, 10.64%
|
|
|
Wiley
19 publications, 8.09%
|
|
|
Frontiers Media S.A.
10 publications, 4.26%
|
|
|
Oxford University Press
5 publications, 2.13%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 1.7%
|
|
|
American Association for Cancer Research (AACR)
4 publications, 1.7%
|
|
|
Taylor & Francis
3 publications, 1.28%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 1.28%
|
|
|
SAGE
3 publications, 1.28%
|
|
|
eLife Sciences Publications
3 publications, 1.28%
|
|
|
Annual Reviews
3 publications, 1.28%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 0.85%
|
|
|
Impact Journals
2 publications, 0.85%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.85%
|
|
|
American Chemical Society (ACS)
2 publications, 0.85%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 0.85%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.85%
|
|
|
AIP Publishing
1 publication, 0.43%
|
|
|
EDP Sciences
1 publication, 0.43%
|
|
|
Portland Press
1 publication, 0.43%
|
|
|
Spandidos Publications
1 publication, 0.43%
|
|
|
American Institute of Mathematical Sciences (AIMS)
1 publication, 0.43%
|
|
|
Rockefeller University Press
1 publication, 0.43%
|
|
|
American Society of Hematology
1 publication, 0.43%
|
|
|
European Molecular Biology Organization
1 publication, 0.43%
|
|
|
American Physical Society (APS)
1 publication, 0.43%
|
|
|
10
20
30
40
50
60
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
235
Total citations:
235
Citations from 2024:
49
(20.85%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Salgia R., Kulkarni P. The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer // Trends in Cancer. 2018. Vol. 4. No. 2. pp. 110-118.
GOST all authors (up to 50)
Copy
Salgia R., Kulkarni P. The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer // Trends in Cancer. 2018. Vol. 4. No. 2. pp. 110-118.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.trecan.2018.01.001
UR - https://doi.org/10.1016/j.trecan.2018.01.001
TI - The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer
T2 - Trends in Cancer
AU - Salgia, Ravi
AU - Kulkarni, Prakash
PY - 2018
DA - 2018/02/03
PB - Elsevier
SP - 110-118
IS - 2
VL - 4
PMID - 29458961
SN - 2405-8033
SN - 2405-8025
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2018_Salgia,
author = {Ravi Salgia and Prakash Kulkarni},
title = {The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer},
journal = {Trends in Cancer},
year = {2018},
volume = {4},
publisher = {Elsevier},
month = {feb},
url = {https://doi.org/10.1016/j.trecan.2018.01.001},
number = {2},
pages = {110--118},
doi = {10.1016/j.trecan.2018.01.001}
}
Cite this
MLA
Copy
Salgia, Ravi, and Prakash Kulkarni. “The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer.” Trends in Cancer, vol. 4, no. 2, Feb. 2018, pp. 110-118. https://doi.org/10.1016/j.trecan.2018.01.001.